Everolimus in liver transplantation

Current Opinion in Organ Transplantation

Volumn 19, Issue 6, 2014, Pages 578-582

  Trotter, James F ^a   Lizardo Sanchez, Luis ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Everolimus; Immunosuppression; Liver transplantation; Mammalian target of rapamycin inhibitor

Indexed keywords

EVEROLIMUS; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; CYTOPENIA; GRAFT FAILURE; GRAFT RECIPIENT; HEPATIC ARTERY THROMBOSIS; HUMAN; HYPERLIPIDEMIA; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MONOTHERAPY; REVIEW; STOMATITIS; WOUND HEALING IMPAIRMENT; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ANIMAL; GRAFT REJECTION;

ANIMALS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; SIROLIMUS; TACROLIMUS;

EID: 84927689293     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000127     Document Type: Review

References (18)

1. Organ Procurement and Transplantation Network. http://optn.transplant.hrsa.gov/data/annualReport.asp. [Accessed 1 August 2014]
2. Trotter JF, Grafals M, Alsina AE. Early use of renal-sparing agents in liver transplantation: a closer look. Liver Transpl 2013; 19:826-842.
3. McKenna GJ, Trotter JF. Sirolimus conversion for renal dysfunction in liver transplant recipients: the devil really is in the details⋯ Am J Transplant 2012; 12:521-522.
4. Levy G, Schmidli H, Punch J, et al. Safety, tolerability, and efficacy of ever-olimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 2006; 12:1640-1648.
5. Fischer L, Klempnauer J, Beckebaum S, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation-PROTECT. Am J Transpl 2012; 12:1855-1865.
6. Sterneck M, Kaiser GM, Heyne N, et al. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am J Transplant 2014; 14:701-710.
7. Masetti M, Montalti R, Rompianesi G, et al. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant 2010; 10:2252-2262.
8. DeSimone P, Nevens F, DeCarlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transpl 2012; 12:3008-3020.
9. Saliba F, DeSimone P, Nevens F, et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transpl 2013; 13:1734-1745.
10. Castroagudín JF, Molina E, Romero R, et al. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Liver Transpl 2009; 15:1792-1797.
11. DeSimone P, Carrai P, Precisi A, et al. Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function. Transpl Int 2009; 22:279-286.
12. DeSimone P, Metselaar HJ, Fischer L, et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl 2009; 15:1262-1269.
13. Saliba F, Dharancy S, Lorho R, et al. Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis. Liver Transpl 2011; 17:905-913.
14. Vallin M, Guillaud O, Morard I, et al. Tolerability of everolimus-based immuno-suppression in maintenance liver transplant recipients. Clin Transpl 2011; 25:660-669.
15. Cholongitas E, Mamou C, Rodríguez-Castro KI, Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int 2014. [Epub ahead of print]
16. Patsenker E, Schneider V, Ledermann M, et al. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol 2011; 55:388-398.
17. McKenna GJ, Trotter JF, Klintmalm E, et al. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transpl 2011; 11:2379-2387.
18. Villamil FG, Gadano AC, Zingale F, et al. Fibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs. calcineurin inhibitors. Liver Int 2013. doi:10.1111/liv.12416.